- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | bioAffinity stellt Forschungsergebnisse zu Hautkrebsbehandlung vor | 1 | Investing.com Deutsch | ||
| Mo | bioAffinity to present skin cancer treatment research | 1 | Investing.com | ||
| 18.06. | WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering | 91 | PR Newswire | JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 18.06. | bioAffinity Technologies closes $3.2M public offering | 1 | Investing.com | ||
| 18.06. | bioAffinity Technologies schließt Kapitalerhöhung über 3,2 Mio. US-Dollar ab | 2 | Investing.com Deutsch | ||
| 16.06. | bioAffinity Technologies, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 16.06. | bioAffinity Technologies, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 16.06. | bioAffinity to participate in veterans lung health webinar | 1 | Investing.com | ||
| 12.06. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 27.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | bioAffinity Technologies, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 12.05. | bioAffinity reports 300% jump in lung test sales in April | 1 | Investing.com | ||
| 08.05. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M | 1 | Seeking Alpha | ||
| 08.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 30.04. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | bioAffinity reports 146% jump in Q1 lung test sales | 7 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,330 | +0,43 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,220 | +4,27 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,030 | 0,00 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,820 | +0,78 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,000 | +0,25 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 70,92 | +2,13 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| ATAIBECKLEY | 4,400 | -4,76 % | AtaiBeckley to join Russell 2000, 3000 indexes | ||
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| ALDEYRA | 1,510 | -6,79 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| ONCO-INNOVATIONS | 0,460 | -2,23 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 18,180 | -1,25 % | Adaptive Biotechnologies Corp - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 6,400 | -1,23 % | ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? | ||
| BIOMERIEUX | 70,75 | 0,00 % | BioMérieux Aktie steigt nach FDA Antrag für Vaginitis Panel | ||
| AC IMMUNE | 2,215 | -1,34 % | AC Immune SA: AC Immune First Quarter 2026 Financial and Corporate Updates | AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers... ► Artikel lesen | |
| 10X GENOMICS | 31,280 | -3,01 % | 10x Genomics, Inc.: 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group | Acquisition Expands 10x Genomics' Capabilities in Proteomics
PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science... ► Artikel lesen |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,844 Euro und damit +1,70 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.